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New malignancies after squamous cell carcinoma
and melanomas: a population-based study from
Norway
Trude E Robsahm1*, Margaret R Karagas2, Judy R Rees2 and Astri Syse3
Abstract
Background: Skin cancer survivors experience an increased risk for subsequent malignancies but the associated risk
factors are poorly understood. This study examined the risk of a new primary cancer following an initial skin cancer
and assessed risk factors associated with second primary cancers.
Methods: All invasive cutaneous malignant melanomas (CMM, N = 28 069) and squamous cell carcinomas (SCC,
N = 24 620) diagnosed in Norway during 1955–2008 were included. Rates of new primary cancers in skin cancer
survivors were compared to rates of primary malignancies in the general population using standardized incidence
ratios (SIR). Discrete-time logistic regression models were applied to individual-level data to estimate cancer risk among
those with and without a prior skin cancer, accounting for residential region, education, income, parenthood, marital
status and parental cancer status, using a 20% random sample of the entire Norwegian population as reference. Further
analyses of the skin cancer cohort were undertaken to determine risk factors related to subsequent cancers.
Results: During follow-up, 9608 new primary cancers occurred after an initial skin cancer. SIR analyses showed 50%
and 90% increased risks for any cancer after CMM and SCC, respectively (p < 0.01). The logistic regression model
suggested even stronger increase after SCC (130%). The highest risk was seen for subsequent skin cancers, but several
non-skin cancers were also diagnosed in excess: oral, lung, colon, breast, prostate, thyroid, leukemia, lymphoma and
central nervous system. Factors that were associated with increased risk of subsequent cancers include male sex, older
age, lower residential latitude, being married and low education and income. Parental cancer did not increase the risk
of a subsequent cancer after SCC, but was a significant predictor among younger CMM survivors.
Conclusions: Our results provide information on shared environmental and genetic risk factors for first and later
cancers and may help to identify individuals at high risk for subsequent cancers, which will be important as skin cancer
incidence continues to rise.
Keywords: Malignant Melanoma, Squamous Cell Carcinoma, Second cancer, Population-based, Sociodemographic
factors, Family
Background
Cutaneous squamous cell carcinoma (SCC) and malig-
nant melanoma (CMM) are among the most prevalent
[1] and rapidly increasing malignancies in white popula-
tions worldwide [2]. In Norway, the incidence of these
cancers has increased sevenfold during the last fifty
years. In 2010, SCC and CMM represented more than
10% of all new cancer cases in Norway [3]. The major
environmental risk factor for all skin cancers is ultravio-
let radiation (UVR) from sunlight; consequently, there is
a distinct north–south gradient in skin cancer risk [4].
The type of UVR exposure (e.g. intermittent versus ac-
cumulated) appears to differ for SCC and CMM [5]. In
addition, individual characteristics such as skin type, eye
and hair color, nevi and immune suppression are im-
portant predictors of individual susceptibility to skin
cancer [6,7]. High socioeconomic status is also associ-
ated with CMM [8].* Correspondence: trude.eid.robsahm@kreftregisteret.no
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SCC is a highly curable disease, and the most recent
five-year relative survival rates in Norway are 89% and
93% for men and women respectively [3]. Although
CMM carries a higher mortality rate, the 5-year survival
rate is still high (77% and 89% for men and women, re-
spectively) [3], due to early diagnosis and successful
treatment. During the last fifteen years, several studies
have suggested that a history of skin cancer increases
the risk for a new primary cancer, both of the skin and
other sites [9-30]. Many of these studies were based on
cancer registry data, with high quality case ascertain-
ment but lacking data on individual risk factors that
might explain this. Other studies have benefitted from
individual exposure data collected using questionnaires,
but these tended to be smaller and have less rigorous
confirmation of skin and subsequent cancers. A reduced
risk of new malignancies after skin cancer has also been
reported for some cancer sites [31-37], which some
argue is due to the potentially protective effect of high
levels of vitamin D that result from UVR exposure [38].
From the Nordic countries, Sweden, Finland and
Denmark have reported their risks of second cancers
after skin cancer [12-14,18,28,29], whereas Norway has
not previously reported on these risks. Therefore, we
used the Norwegian Cancer Registry data to describe the
risk of a new primary cancer following SCC or CMM,
and to further assess whether sociodemographic factors
or cancer family history were associated with risk of sub-
sequent cancers after skin cancer. Identifying those at
greatest risk for subsequent cancers may benefit future
public health initiatives by targeting interventions appro-




Our study cohort included all persons with a histologi-
cally verified invasive cutaneous malignant melanoma
(N = 28 069) or squamous cell carcinoma (N = 24 620)
diagnosed as a first primary cancer in the period 1955–
2008 (Table 1). The Cancer Registry of Norway has regis-
tered all cancer diagnoses nationwide from 1953 onwards
(not including basal cell carcinoma of skin). Mandatory
reporting from multiple independent sources ensures the
collection of complete and high quality data [39]. Avail-
able information includes date and type of primary skin
cancer diagnosis, stage, and anatomical location (head/
neck, trunk, arm, leg/foot or other sites) as well as similar
data on subsequent cancers. To distinguish new primary
cancers from recurrences, the Cancer Registry uses histo-
logical information and medical record review; if the hist-
ology reports are similar, at least four months must have
passed since the initial cancer diagnosis for a later case to
be defined as a new primary cancer and clinical records
must be consistent with a new primary according to the
cancer registry standard [39].
The Norwegian Population Register, the Norwegian
Education Register and the Norwegian Directorate of
Taxes provided information for the cases as well as the
general population on individual level characteristics
such as date of birth, emigration and death, residential
region, attained educational level (1960, 1970, and yearly
from 1980 onwards), income (annual from 1966 on-
wards), parity, and marital status. The data were linked
through unique personal identification numbers assigned
to every individual residing in Norway from 1960 on-
wards. Permission to match the data was provided by
the National Data Inspectorate in Norway after ethical
review of this study by the Norwegian Board of Medical
Ethics.
For our study, we obtained individual-level data on all
residents during the period 1955–2008 (N = 5.3 million).
We used all skin cancer cases and a 20% random sample
of the entire population for comparison (N = 1.1 million).
Follow-up for skin cancer cases began on the date of diag-
nosis. For the general population, follow-up began either
at age 20 or age in 1955 if greater than 20 at that time.
Age and calendar period were included as time-varying
covariates, 20–39, 40–59 and ≥ 60 years and 1955–64,
1965–74, 1975–84, 1985–94, 1995–2004 and 2005 and
above, respectively. As the majority of Norwegians have
completed their education by age 25 and having children
by age 35 for the time period under consideration, we
used educational level and parental status at end of
follow-up in our models. For residential region, marital
status and income, we modeled status at the start of
follow-up. The average follow-up time was 10.1 years for
skin cancer survivors, and 30.6 years for the general
population.
We examined the associations between an initial skin
cancer and new primary cancers of the skin as well as
mouth/pharynx, lung, breast, prostate, thyroid, leukemia
and lymphomas, which are the sites with the most evi-
dence of an association in earlier studies [10-12,14-16,19,
21,23,25-30]. Exploratory analyses were also undertaken
to examine the risk of second cancer at other common
sites.
We examined the risk of second cancers by age at
diagnosis because young age at onset of the initial cancer
may indicate a genetic predisposition. We examined
residence by latitude (South, Mid and North, as previ-
ously described [40]) because the association between
skin cancer and subsequent malignancies is hypothesized
to be strongest further from the equator [21]. To ac-
count for detection bias attributable to increased atten-
tion to cancer symptoms after a skin cancer diagnosis,
we also examined the short- and long-term risks of sub-
sequent cancer after diagnosis of a primary skin cancer.
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Table 1 Descriptive features of the cohort of persons with a first primary cutaneous malignant melanoma (CMM) or
squamous cell carcinoma (SCC) at time of the primary skin cancer diagnosis
CMM SCC
Women % Men % Women % Men %
Age at 1st diagnosis
20-40 3249 21.5 1943 15.0 248 2.3 270 2.0
40-59 5435 35.9 4908 38.0 1201 11.0 1492 10.9
≥ 60 6452 42.6 6082 47.0 9474 86.7 11 935 87.1
Age (median) 55.6 57.4 75.4 73.2
Anatomical site
Head/neck 2148 14.2 2025 15.7 6560 60.0 8809 64.3
Trunk 4353 28.8 7044 54.4 1659 15.2 2071 15.1
Arm 2346 15.5 1188 9.2 1103 10.1 1281 9.4
Leg/foot 5633 37.2 1786 13.8 1060 9.7 737 5.4
Other sites 656 4.3 890 6.9 541 5.0 799 5.8
Residential region
South 10 875 71.9 9270 71.7 7878 72.1 9537 69.6
Mid 2998 19.8 2525 19.5 2235 20.5 2877 21.0
North 1263 8.3 1138 8.8 810 7.4 1283 9.4
Educational level
≤ Primary school 496 3.3 617 4.8 420 3.8 653 4.8
Secondary school 5199 34.4 3446 26.6 5678 52.0 5847 42.7
Some college 4545 30.0 3271 25.3 3106 28.4 3359 24.5
≥ College degree 4896 32.3 5599 43.3 1719 15.8 3830 28.0
Marital status
Not married 6270 41.4 3515 27.2 6981 63.9 4641 33.9
Married 8866 58.6 9418 72.8 3942 36.1 9056 66.1
Parental status
No children 3875 25.6 2989 23.1 3855 35.3 4226 30.9
Children 11 261 74.4 9944 76.9 7068 64.7 9471 69.1
Annual income
No or missing 6467 42.7 4118 31.8 8930 81.7 9523 69.5
$ 1-9999 2573 17.0 1639 12.7 801 7.3 1609 11.8
$ 10 000–19 999 1712 11.3 1283 9.9 320 3.0 567 4.1
$ 20 000–39 999 2326 15.4 2166 16.8 462 4.2 782 5.7
$ ≥ 40 000 2058 13.6 3727 28.8 410 3.8 1216 8.9
Duration of follow-up (years)
0.0-2.0 2551 16.9 3050 23.6 2642 24.2 3491 25.5
2.1-5.0 2938 19.4 3235 25.0 3019 27.6 3875 28.3
5.1-10.0 3044 20.1 2610 20.2 2658 24.3 3427 25.0
10.1-15.0 2261 14.9 1577 12.2 1398 12.8 1655 12.1
15.1-20.0 1720 11.4 1088 8.4 648 6.0 690 5.0
20.1-25.0 1109 7.3 615 4.8 289 2.6 313 2.3
≥ 25.1 1513 10.0 758 5.8 269 2.5 246 1.8
Total number 15 136 100 12 933 100 10 923 100 13 697 100
No subsequent cancer 13 078 86.4 10 995 85.0 9030 82.7 9978 72.9
Any subsequent cancer 2058 13.6 1938 15.0 1893 17.3 3719 27.1
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We obtained information on parental cancer diagnoses
for the skin cancer survivors who had identified parents
(i.e. were alive in 1960). Overall, we were able to link
60% of the skin cancer survivors with their mother and
55% with their father. In general, the linkage rate de-
creased with increasing age at diagnosis, and we thus
performed analyses stratified by year of birth (all, birth
year > 1930 and birth year > 1950).
Statistical analyses
Three types of analyses were conducted. First, we used
standardized incidence ratios (SIR) to compare rates of
subsequent malignancies in skin cancer survivors with
rates of first primary cancer in subgroups of the general
population of comparable age, sex and calendar time.
The person-years at risk and the observed number of
cancer cases were counted by sex within 5-year age
groups (20–24, …, 80–84, 85+), and 5-year calendar pe-
riods (1955–59, …, 2000–04), except for the last period
which ran from 2005–08. The expected number of can-
cer cases was calculated by multiplying the number of
person-years in each age group and calendar period in
the skin cancer cohort by the corresponding cancer rates
in the general Norwegian population. The 95% confidence
interval (CI) for the SIR was based on the assumption that
the observed number of cases was Poisson-distributed and
the expected number was non-stochastic. The analyses
were performed using Stata 12 [41].
Second, a discrete-time logistic regression model was
used to assess the importance of individual-level risk
factors for the risk of a new primary cancer after skin
cancer versus a first primary malignancy. Series of
twelve-month observations were created for each indi-
vidual. Individuals were followed from start of follow-up
to a first primary malignancy (in a 20% random selection
of the general population) or a subsequent malignancy
(in skin cancer survivors). Individuals were followed to
2008, unless death, emigration or a malignancy occurred
before this time. The follow-up time was categorized as
0–2 years, 3–5 years, 6–10 years, 11–15 years, 16–
20 years, 21–25 years or more than 25 years. Categoriza-
tions of the covariates are shown in Table 2. Interaction
terms between a primary skin cancer diagnosis and the
various sociodemographic features were included to as-
sess possible effect modification. Based on these results,
stratified analyses were undertaken on variables for
which effect modification appeared to be present.
Third, internal analyses were undertaken to examine
whether cancer-related and sociodemographic factors in-
fluence the risk of subsequent malignancies within the
cohort of skin cancer survivors. The analyses explored
the possible impact of the anatomic site of the primary
skin cancer and history of parental cancer. All the
discrete-time models were run using the PROC
LOGISTIC procedure in SAS 9.2 [42]. Time to subse-
quent malignancies in men and women was explored
using Kaplan-Meier plots, separately for CMM (Figure 1A)
and SCC (Figure 1B) survivors, using Stata 12 [41]. The
statistical significance level was set at 5%.
Results
Overall, 3996 and 5612 subsequent cancers occurred, re-
spectively, among CMM and SCC survivors during
follow-up. The characteristics of individuals diagnosed
with skin cancer are displayed in Table 1. CMM patients
were diagnosed at an earlier age, were better educated,
had higher incomes, were more frequently married and
had children than SCC patients.
Standard incidence ratios (SIR)
We found 50% and 90% increases in the risks of subsequent
cancer after an initial CMM and a SCC diagnosis, respect-
ively (Tables 3, 4). The strongest risks were observed for
subsequent skin cancers, and in particular for skin cancers
of the same histology as the index cancer. Increased risks
were also observed for several non-skin cancers (thyroid,
breast, prostate, leukemia and lymphomas) after both types
of skin cancer. After CMM, a 30% increase in risk of central
nervous system (CNS) tumors was observed and in men
we observed a decreased risk of lung cancer. After SCC,
more than a threefold and a sixfold risk increase was ob-
served for mouth/pharynx and salivary gland tumors re-
spectively, as well as a nearly 50% risk increase for lung
cancer. Further, the risks of pancreatic and colon cancer
were significantly elevated in both sexes, but in women we
found a decreased risk of cancers of urinary organs.
Logistic regression models
As several cancer forms are associated with socioeco-
nomic status, site-specific analyses controlling for sociode-
mographic and -economic risk factors were conducted.
Results were fairly similar to those observed in the SIR
analyses (Table 5), e.g., for the risk of breast cancer after
either CMM or SCC. However, the model resulted in
higher risk estimates for leukemia, lymphoma and colon
cancer after CMM or SCC and for cancers of urinary or-
gans after SCC. For prostate cancer there was a lower esti-
mate after CMM but higher after SCC.
Table 2 shows estimates from a fully saturated
discrete-time logistic regression model, comparing the
risk of a first cancer in the general population with that
of a second cancer in skin cancer survivors. Compared
to the general population, the cancer risk was approxi-
mately 50% and 130% higher after an initial CMM and
SCC, respectively. An increased cancer risk was associ-
ated with male sex, older age, lower residential latitude,
recent calendar time, primary education, low income
and being married.
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In the comparison between CMM survivors and the
general population, interactions were observed for educa-
tional attainment, attained age and calendar period
(pinteraction < 0.01). In stratified analyses, the risk of a subse-
quent cancer was higher for CMM survivors with an edu-
cation at college or university level (Odds ratio (OR) 1.65,
Table 2 Odds ratios (OR) and 95% confidence intervals (CI) from a fully saturated discrete-time logistic regression model,
comparing the risk of a first cancer in the general population with that of a second cancer in skin cancer survivors
CMM SCC
Events/Pyr1 OR (95% CI) Events/Pyr OR (95% CI)
Primary skin cancer
No 143 978/31.0 mill 1.00 ref 144 179/31.0 mill 1.00 ref
Yes 3662/288 823 1.53 (1.48,1.59) 5612/175 641 2.30 (2.22,2.37)
Sex
Female 72 768/15.8 mill 1.00 ref 72 319/15.7 mill 1.00 ref
Male 75 206/15.4 mill 1.28 (1.26,1.29) 77 472/15.4 mill 1.31 (1.29,1.32)
Age2
20-40 years 6447/12.0 mill 1.00 ref 6509/12.0 mill 1.00 ref
40-59 years 30 795/10.6 mill 5.37 (5.22,5.52) 30 241/10.5 mill 5.28 (5.14,5.43)
≥ 60 years 110 732/8.6 mill 20.58 (20.04,21.14) 113 041/8.6 mill 20.34 (19.80,20.9)
Residential region3
North 21 277/6.0 mill 1.00 ref 21 323/6.0 mill 1.00 ref
Mid 34 586/7.2 mill 1.30 (1.27,1.32) 34878/7.2 mill 1.30 (1.28,1.32)
South 92 111/18.0 mill 1.33 (1.31,1.35) 93 590/17.9 mill 1.35 (1.33,1.37)
Calendar period2
< 1965 8477/4.3 mill 1.00 ref 8354/4.3 mill 1.00 ref
1965-1974 20 484/5.4 mill 2.54 (2.47,2.61) 20 867/5.4 mill 2.62 (2.56,2.6)
1975-1984 27 276/5.9 mill 3.63 (3.54,3.73) 27 573/5.9 mill 3.73 (3.63,3.83)
1985-1994 33 071/6.3 mill 4.28 (4.17,4.40) 33 817/6.3 mill 4.45 (4.34,4.57)
1995-2004 40 142/6.6 mill 5.33 (5.19,5.47) 40 241/6.6 mill 5.41 (5.27,5.56)
≥ 2005 18 524/2.7 mill 5.99 (5.82,6.17) 18 939/2.6 mill 6.22 (6.04,6.40)
Educational level4
≤ Primary school 15 926/1.9 mill 1.00 ref 16 141/1.9 mill 1.00 ref
Secondary school 67 042/11.8 mill 0.32 (0.31,0.33) 67 915/11.8 mill 0.32 (0.31,0.33)
Some college 35 646/7.0 mill 0.30 (0.29,0.31) 36 079/7.0 mill 0.30 (0.29,0.30)
≥ College degree 29 360/10.5 mill 0.30 (0.29,0.31) 29 656/10.4 mill 0.30 (0.30,0.31)
Marital status3
Not married 47 085/15.7 mill 1.00 ref 47 881/15.7 mill 1.00 ref
Married 100 889/15.5 mill 1.25 (1.24,1.27) 101 910/15.4 mill 1.27 (1.25,1.28)
Parental status4
No children 138 424/28.9 mill 1.00 ref 139 451/28.9 mill 1.00 ref
Children 9550/2.3 mill 0.95 (0.93,0.97) 10 340/2.2 mill 0.96 (0.94,0.98)
Income (annual)3
$ 05 60 395/9.1 mill 1.00 ref 62 871/9.1 mill 1.00 ref
$ 80–9 999 40 528/10.7 mill 0.92 (0.90,0.93) 40 556/10.7 mill 0.91 (0.90,0.92)
$ 10 000–19 999 34 425/8.7 mill 0.80 (0.79,0.82) 34 394/8.7 mill 0.80 (0.78,0.80)
$ 20 000–39 999 11 582/2.6 mill 0.78 (0.77,0.80) 11 140/2.5 mill 0.76 (0.74,0.78)
$ ≥ 40 000 1044/153 034 0.82 (0.77,0.87) 830/122 013 0.78 (0.73,0.84)
1Number of events (new cancers) per person-year during follow-up. 2Time-varying covariates (yearly). 3At start of follow-up. 4At end of follow-up. 5Includes also
those with missing income data.
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CI 1.57-1.74) than for those with a lower education (OR
1.34, CI 1.26-1.42). Similarly, a CMM diagnosis before the
age of 60 significantly increased the risk of a subsequent
cancer (OR 2.59, CI 2.41-2.79) compared to those older
than 60 years (OR 1.43, CI 1.37-1.50). The interaction term
between calendar year as a linear variable and CMM
diagnosis suggested an increase in risk with more recent
calendar time. However, splitting the sample at year 1990
did not identify appreciable differences (≤ 1990: OR 1.57,
CI 1.50-1.64 vs. > 1990: OR 1.64, CI 1.52-1.77).
For SCC survivors in comparison to the general popu-
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Figure 1 Kaplan-Meier plots of the timing of a second malignancy for men and women after a primary diagnosis of cutaneous
malignant melanoma (A) and a primary diagnosis of cutaneous squamous cell carcinoma (B).
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educational attainment, attained age and calendar period
(pinteraction < 0.01). Risk for a subsequent cancer was
higher for SCC survivors with at least one child (OR
2.64, CI 2.48-2.80) compared to those without children
(OR 2.26, CI 2.15-2.37). Further, a higher risk of subse-
quent cancer was observed for SCC survivors with an
education at college or university level (OR 2.49, CI
2.38-2.62) compared to those with a lower education
(OR 1.97, CI 1.89-2.06). SCC diagnosis before the age
of 60 was associated with a higher risk of subsequent
cancer (OR 5.54, CI 4.88-6.29) compared to those
older than 60 years (OR 2.07, CI 2.00-2.15). Risk of
subsequent cancer was also higher after 1990 (OR
2.52, CI 2.42-2.62) than prior to this (OR 2.29, CI
2.15-2.42).
Risk of subsequent cancer among skin cancer survivors
The results for the internal comparisons were quite
similar for the two subgroups of skin cancer survivors
and they confirmed the findings from the external ana-
lyses (Table 6). No clear difference in the overall risk of
subsequent cancer was found across the anatomical
sites of the primary skin cancer, after CMM or SCC
(data not shown). This was true for all cancer sites, skin
included.
Parental cancer
The risk for a new primary cancer after an initial CMM
was not associated with a history of cancer in their mother
(OR 1.05, CI 0.90-1.23), father (OR 0.95, CI 0.81-1.11) or
either parent (OR 1.00, CI 0.88-1.13), for individuals born
after 1930. When we restricted the analyses to those with
complete parental linkage (individuals born after 1950),
the respective estimates were elevated; risks of cancer after
CMM in individuals with a history of cancer in their
mother, father or either parent were 1.39 (CI 1.09-1.78),
1.38 (CI 1.09-1.76) and 1.52 (CI 1.21-1.92) respectively.
For SCC survivors, the estimates associated with parental
cancer were not significantly elevated in the overall or re-
stricted analyses (data not shown).
Time since first primary cancer
The risk of subsequent cancer after an initial skin cancer
increased with time and the risk excess was greater for
men than for women (Figures 1A and B). Whereas the
increase appeared almost linear for CMM survivors, it
rose in a non-linear manner for SCC survivors.
Table 3 Standard incidence ratios (SIR) with 95% confidence intervals (CI) for a second malignancy by cancer site in
men and women with a history of cutaneous malignant melanoma (CMM), adjusted for age and calendar period
Women (N = 15 1841) Men (N = 12 9721)
ICD-10 Cancer site2 O3 SIR (95% CI) O3 SIR (95% CI)
C00-14 Mouth, pharynx 14 0.77 (0.46,1.30) 33 1.11 (0.79,1.56)
C18 Colon 163 1.02 (0.88,1.19) 134 1.16 (0.98,1.37)
C19-21 Rectum 57 0.87 (0.67,1.13) 62 0.93 (0.72,1.19)
C25 Pancreas 46 1.00 (0.76,1.33) 39 1.06 (0.77,1.45)
C33,34,38 Lung 109 1.12 (0.93,1.35) 119 0.72 (0.60,0.87)
C50 Breast 377 1.24 (1.12,1.37) - -
C50-58 Female organs 588 1.18 (1.09,1.28) - -
C61 Prostate - - 445 1.26 (1.15,1.38)
C64-68 Urinary organs 68 0.93 (0.73,1.18) 139 0.99 (0.84,1.17)
C70-72 CNS4 70 1.39 (1.09,1.75) 41 1.31 (0.98,1.78)
C73 Thyroid 19 1.27 (0.81,1.99) 13 2.78 (1.61,4.80)
C81-85 Lymphoma 56 1.29 (0.99,1.68) 60 1.56 (1.20,1.99)
C91-95 Leukemia 72 1.28 (1.01,1.60) 64 1.22 (0.87,1.43)
C00-965 Other sites 169 1.15 (0.99,1.34) 176 1.07 (0.92,1.24)
C43 CMM 438 7.59 (6.91,8.33) 411 9.44 (8.57,10.4)
C44 SCC 197 3.12 (2.71,3.59) 204 3.11 (2.71,3.56)
C00-96 All sites 2066 1.52 (1.46,1.59) 1943 1.49 (1.43,1.60)
C00-966 All, exc. skin 1431 1.16 (1.11,1.23) 1328 1.12 (1.06,1.18)
C00-967 All, exc. CMM 1628 1.26 (1.20,1.32) 1532 1.25 (1.19,1.31)
1The number of cancer cases in the SIR-analyses differs slightly from that used in the logistic regression analyses as the data were extracted on different dates
from the Cancer Registry of Norway. 2The cancer sites are not mutually exclusive. 3Observed number of cases. 4Central nervous system tumors. 5Includes ICD-10
codes C15-17, C22-24, C26, C30-32, C37, C39-41, C45-49, C60, C62-63, C69, C74-76, C80, C88, C90. 6All sites except C43 and C44. 7All sites except C43.
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Discussion
The risk of a new primary cancer was higher after an ini-
tial skin cancer compared to the risk of a first primary
cancer in the general Norwegian population, using mul-
tiple approaches. The highest risk was found for a subse-
quent skin cancer, but several non-skin cancers were
also diagnosed in excess including oral, colon, lung,
breast, prostate, urinary organs, CNS, thyroid, leukemia
and lymphomas. Many of the associations we observed
have been reported previously, but we were able to ac-
count for a number of sociodemographic factors, and
show that the risks remained elevated. Among skin can-
cer survivors an elevated risk of subsequent cancer was
associated with male sex, older age, lower residential
latitude, primary education only, low income and being
married and the risk increased over the study period.
Having children was associated with a slightly decreased
cancer risk. Having a parent with a history of cancer in-
creased the risk for a new primary cancer after CMM if
diagnosed before age 60.
Individual risk of skin cancer is determined by UVR and
host susceptibility [43]. These are the likely explanations
for the increased risk of skin and perhaps lip cancer after
a CMM or SCC diagnosis, but medical surveillance after
the diagnosis may also be important. However, the reasons
why individuals with a history of skin cancer have a higher
risk of non-cutaneous malignancies, than those without a
skin cancer history, are less obvious.
As in previous reports [9,10,14-16,18,19,21-23,25-30,36],
we also observed that a history of skin cancer increased
the risk of leukemia and lymphoma. Although the mech-
anism for such an association is not fully understood, sev-
eral mechanisms have been suggested. First, UVR impairs
the immune system, both locally in the skin and systemic-
ally [44-46]. Moreover, immunodeficiency as a result of
the disease itself [27,47,48], genetic factors [44] or previ-
ous treatment with radiation or chemotherapy [49,50], are
all potentially shared risk factors.
We found a history of SCC to be related to an in-
creased risk of lung and mouth/pharynx cancers which
is consistent with several previous observations [9,12,16,
19-21,23,24,26-30,51]. Although UVR has been sug-
gested to play a role also for these cancer types, similar
relationships were not observed after CMM. The most
Table 4 Standard incidence ratios (SIR) and 95% confidence intervals (CI) for a second malignancy by cancer site in
men and women with a history of cutaneous squamous cell carcinoma (SCC), adjusted for age and calendar period
Women (N = 10 9651) Men (N = 13 7481)
ICD-10 Cancer site2 O3 SIR (95% CI) O3 SIR (95% CI)
C00-144 Mouth, pharynx 38 3.03 (2.20,4.16) 114 3.23 (2.69,3.87)
C07-08 Salivary glands 11 6.69 (3.71,12.1) 17 6.19 (3.85,9.95)
C18 Colon 176 1.25 (1.08,1.45) 197 1.09 (0.95,1.25)
C19-21 Rectum 45 0.86 (0.64,1.14) 96 0.98 (0.80,1.20)
C25 Pancreas 45 1.03 (0.77,1.38) 82 1.39 (1.12,1.73)
C33,34,38 Lung 82 1.46 (1.17,1.81) 303 1.49 (1.32,1.66)
C50 Breast 204 1.15 (1.00,1.32) - -
C50-58 Female organs 320 1.11 (0.99,1.24) - -
C61 Prostate - - 650 1.14 (1.06,1.23)
C64-68 Urinary organs 42 0.69 (0.51,0.94) 222 1.08 (0.94,1.23)
C70-72 CNS5 17 0.65 (0.40,1.04) 32 1.10 (0.78,1.56)
C73 Thyroid 12 7.30 (4.15,12.8) 3 0.60 (0.19,1.85)
C81-85 Lymphoma 64 2.14 (1.67,2.74) 113 2.41 (2.00,2.90)
C91-95 Leukemia 65 1.33 (1.04,1.69) 150 1.70 (1.45,1.99)
C00-966 Other sites 183 1.13 (0.98,1.31) 371 1.37 (1.23,1.51)
C43 CMM 95 3.09 (2.52,3.78) 122 2.76 (2.31,3.29)
C44 SCC 715 9.88 (9.18,10,6) 1249 10.1 (9.51,10.6)
C00-96 All sites 1898 1.89 (1.81,1.98) 3725 1.91 (1.84,1.96)
C00-967 All, exc. skin 1088 1.22 (1.15,1.30) 2354 1.33 (1.28,1.39)
C00-968 All, exc. SCC 1183 1.23 (1.16,1.30) 2476 1.31 (1.25,1.36)
1The number of cancer cases in the SIR-analyses differs slightly from that used in the logistic regression analyses as the data were extracted on different dates
from the Cancer Registry of Norway. 2The cancer sites are not mutually exclusive. 3Observed number of cases. 4Includes ICD-10 codes C00-06 and C09-14. 5Central
nervous system tumors. 6Includes ICD-10 codes C15-17, C22-24, C26, C30-32, C37, C39-41, C45-49, C60, C62-63, C69, C74-76, C80, C88, C90. 7All sites except C43
and C44. 8All sites except C44.
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reasonable explanation for the increased risk of lung and
oral cancer in SCC survivors may be related to tobacco
use, which also has been suggested as a risk factor for
SCC [29,51]. Moreover, a primary SCC was associated
with an increased risk of cancer in urinary organs that also
might be related to tobacco. While we have no informa-
tion on tobacco use, prior studies that were able to control
for tobacco use still observed an increased risk of lung
[20,30], oral and kidney cancers [30]. Thus, it is possible
that the relationship observed between SCC and cancers
of mouth/pharynx, lung, and urinary organs lies elsewhere.
The risk of thyroid cancer was significantly increased,
both after an initial CMM (both sexes) and SCC (women
only), also consistent with previous findings [11,21,
25-27,31]. Common risk factors such as genetic or envir-
onmental exposure have been suggested to explain this
association [25]. A cancer diagnosis may also increase
future health vigilance, which may result in increased
detection of new malignancies. Physical examination for
CMM includes lymph node palpation in the thyroid area
and we cannot exclude the possibility of such surveillance
bias. Unfortunately, our numbers were too small to enable
a detailed analysis of the development of thyroid cancer
with time from a primary skin cancer diagnosis.
With respect to the elevated risk of CNS tumors, we
cannot exclude the possibility that the second primary
cancer, reported by the clinicians as a CNS tumor, could
in some patients be a metastasis from the primary
CMM. As CMM but not SCC is likely to spread to the
brain, this may explain why no such association was ob-
served between SCC and risk of CNS tumors.
In line with previous studies [10,15,21,25,27,33,34,52],
an initial skin cancer diagnosis was found to be associ-
ated with an increased risk of colon, breast and prostate
cancer. For breast cancer, the relationship was most pro-
nounced after a primary diagnosis of CMM. Shared hor-
monal mechanisms for CMM and breast cancer have
been proposed, although the epidemiological evidence of
the role of hormones in melanoma etiology is inconsist-
ent [52]. All these three cancer forms, as well as skin
cancer, are associated with high socioeconomic status,
and shared risk factors linked to socioeconomic status
may account for the positive relationship, including fre-
quent screening activity [25,34]. For CMM survivors this
Table 5 Odds ratios (OR) and 95% confidence intervals (CI) of subsequent cancer by cancer site for cohorts with a
primary cutaneous malignant melanoma (CMM) or cutaneous squamous cell carcinoma (SCC) relative to that of the
general population, adjusted for covariates shown in Table 21
CMM SCC
ICD-10 Cancer site2 Events3 OR (95% CI) Events OR (95% CI)
C00-144 Oral cavity 2768 0.96 (0.68,1.34) 2876 2.70 (2.19,3.34)
C07-08 Salivary glands 257 0.62 (0.14,2.74) 291 8.89 (5.29,14.93)
C18 Colon 13 281 1.28 (1.12,1.46) 13 190 1.62 (1.43,1.82)
C19-21 Rectum 6696 1.15 (0.93,1.42) 6768 1.10 (0.91,1.33)
C25 Pancreas 4551 1.14 (0.89,1.45) 4590 1.56 (1.27,1.91)
C33,34,38 Lung 12 347 0.72 (0.62,0.84) 12 613 1.23 (1.09,1.36)
C50 Breast 17 275 1.21 (1.07,1.36) 16 956 1.16 (1.01,1.34)
C50-58 Female organs 29 775 1.11 (1.02,1.22) 29 349 1.08 (0.96,1.21)
C61 Prostate 17 398 1.17 (1.02,1.34) 17 797 1.28 (1.14,1.43)
C64-68 Urinary organs 10 607 1.00 (0.85,1.18) 10 787 1.18 (1.03,1.37)
C70-72 CNS5 4348 1.73 (1.39,2.15) 4149 1.07 (0.79,1.44)
C73 Thyroid 1437 1.75 (1.19,2.56) 1435 1.27 (0.75,2.16)
C81-85 Lymphoma 4672 1.42 (1.14,1.76) 4678 2.78 (2.33,3.32)
C91-95 Leukemia 6096 1.63 (1.33,1.99) 6162 2.15 (1.83,2.53)
C00-966 Other sites 21 969 1.27 (1.13,1.43) 22 373 1.67 (1.51,1.84)
C43 CMM 6363 7.99 (7.19,8.88) 5827 3.45 (2.94,4.05)
C44 SCC 5382 3.31 (2.86,3.82) 6906 14.4 (13.2,15.7)
C00-96 All sites 147 974 1.53 (1.48,1.59) 149 791 2.30 (2.22,2.37)
C00-967 All, exc. skin 136 229 1.16 (1.11,1.21) 137 058 1.51 (1.46,1.57)
1The number of cancer cases in the SIR-analyses differs slightly from that used in the logistic regression analyses as the data were extracted on different dates
from the Cancer Registry of Norway. The number of cases are nevertheless quite similar (CMM: SIR 28 156 vs 28 069, events 4009 vs 3996 and SCC: SIR 24 713 vs
24 620, event 5623 vs 5612). 2The cancer sites are mutually exclusive. 3Observed number of events in a 20% general population sample and the cohort of skin
cancer survivors. 4Includes ICD-10 codes C00-06 and C09-14. 5Central nervous system tumors. 6Includes ICD-10 codes 150–152, 155, 156, 158–161, 164, 178, 179,
192, and 195–199. 7All sites except C43 and C44.
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is somewhat confirmed by the lowering of the risk esti-
mates for breast and prostate cancer once socioeco-
nomic factors were taken into account. In contrast, for
SCC survivors, the risk estimates for these three cancers
rose when accounting for socioeconomic factors.
Sociodemographic factors
Several cancer diseases are strongly associated with so-
cioeconomic resources [53] and socioeconomic factors
have been suggested to represent mediators by which
environmental risk factors vary within a population. In
Table 6 Odd ratios (OR) and 95% confidence intervals (CI) from a fully saturated discrete-time logistic regression
model examining the risk for a subsequent cancer diagnosis within the cohorts with a primary cutaneous malignant
melanoma (CMM) or squamous cell carcinoma (SCC)
CMM SCC
Events/Pyr1 OR (95% CI) Events/Pyr OR (95% CI)
Sex
Female 2058/173 679 1.00 ref 1893/81 108 1.00 ref
Male 1938/115 144 1.51 (1.41,1.63) 3719/94 533 1.90 (1.79,2.01)
Age2
< 40 years 80/31 862 1.00 ref 19/3020 1.00 ref
40-59 years 807/106 669 2.89 (2.29,3.65) 222//17 362 2.28 (1.42,3.66)
≥ 60 years 3109/147 183 6.67 (5.31,8.39) 5371/155 259 4.62 (2.93,7.29)
Residential region3
North 275/23 927 1.00 ref 419/15 325 1.00 ref
Mid 703/54 955 1.09 (0.95,1.26) 1124/37 786 1.09 (0.98,1.23)
South 3018/209 941 1.20 (1.06,1.36) 4069/122 530 1.20 (1.08,1.33)
Calendar period2
< 1965 6/2959 1.00 ref 35/4411 1.00 ref
1965-1974 71/13 448 3.01 (1.30,6.98) 168/10 542 2.51 (1.73,3.64)
1975-1984 276/34 380 4.92 (2.15,11.24) 438/22 580 3.61 (2.50,5.20)
1985-1994 913/69 763 7.80 (3.43,17.34) 1281/40 225 6.46 (4.52,9.24)
1995-2004 1707/112 983 8.88 (3.91,20.17) 2364/64 765 7.76 (5.44,11.1)
≥ 2004 1023/55 290 10.52 (4.63,23.9) 1326/33 118 8.73 (6.10,12.5)
Educational level4
≤ Primary 63/5193 1.00 ref 178/6203 1.00 ref
Secondary 1285/85 407 0.80 (0.61,1.04) 2514/82 333 0.60 (0.50,0.71)
Some college 1293/85 733 0.79 (0.60,1.05) 1577/46 489 0.60 (0.50,0.72)
≥ College degree 1355/112 490 0.80 (0.61,1.05) 1343/40 616 0.61 (0.51,0.74)
Marital status3
Not married 1089/84 671 1.00 ref 2161/72 265 1.00 ref
Married 2907/204 152 1.02 (0.94,1.10) 3451/103 376 1.01 (0.95,1.08)
Parental status4
No children 881/68 530 1.00 ref 1692/56 884 1.00 ref
Children 3115/220 293 0.91 (0.84,0.99) 3920/118 757 0.93 (0.87,0.99)
Income (annual)3
$ 05 1586/81 524 1.00 ref 3982/113 773 1.00 ref
$ 80–9 999 679/57 594 0.83 (0.75,0.91) 715/24 518 0.85 (0.78,0.92)
$ 10 000–19 999 514/50 340 0.68 (0.61,0.75) 300/12 099 0.76 (0.67,0.85)
$ 20 000–39 999 713/57 131 0.75 (0.68,0.82) 334/13 692 0.65 (0.58,0.74)
$ ≥ 40 000 504/42 234 0.65 (0.58,0.73) 281/11 559 0.59 (0.51,0.67)
1Number of events (new cancers) per person-year during follow-up. 2Time-varying covariates (yearly). 3At start of follow-up. 4At end of follow-up. 5Includes also
those with missing income data.
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the present study we observed the highest cancer risk in
the lowest educational and income levels, and it is likely
that this may be attributed to shared adverse lifestyle
factors (i.e. smoking habits, alcohol intake, sun protec-
tion, diet). The Norwegian health care system intends to
ensure equal health care for all inhabitants, independent
of socioeconomic level. Nevertheless, individuals who
belong to a lower social class tend to have lower health
vigilance and participation in surveys and screening pro-
grams to minimize the burden of cancer [54,55]. There-
fore, we cannot exclude the possibility that our results,
at least partly, might be influenced by such mechanisms.
The high risk observed in the elderly may be due to
changed sun exposure habits and increased outdoor ac-
tivities after retirement [56], but there may also be an ef-
fect of an age-related diminished immune response
[57,58]. Analyses stratified by age, on the other hand,
showed that compared to persons in the general popula-
tion, the risk of a second primary cancer was greatest for
the youngest skin cancer survivors, particularly for SCC
survivors. A possible explanation might be a genetic sus-
ceptibility to skin cancer, which is associated with young
age at diagnosis [59], and such susceptibility may also in-
crease the risk for subsequent cancers. Further, the
stronger effect of young age seen for SCC survivors may
be due to the different patterns of UVR exposure associ-
ated with the two skin cancer types (intermittent/accumu-
lated) and to behavior after diagnosis. A CMM diagnosis
may, because of its lethal potential, lead to a more sun-
protective behavior compared to a SCC diagnosis.
Moreover, steep increases in skin cancer rates over
time has been suggested to reflect increased UVR doses
[56], and this may in part explain the observed increase
of subsequent cancers by calendar time.
The status of being married was associated with an in-
creased risk of subsequent cancer after skin cancer, while
having children slightly decreased the risk. Having a
family influences the lifestyle in several ways, as they
may help ensure more optimal medical surveillance as
well as reinforce better health behaviors after diagnosis
(i.e. smoking habits, alcohol intake, sun protection, diet,
screening attendance) [60], which may cause these
relationships.
Parental cancer
Young age at onset of the initial cancer may be an indi-
cation of a genetic predisposition [61]. Contrary to pre-
viously reported work [21,62,63], having a parent with
cancer did not generally increase the risk of being diag-
nosed with a subsequent malignancy. However, analyses
restricted to individuals born after 1950, showed a near
50% increase in risk when either parent had a history of
cancer. Disentangling the effect of age and parental can-
cer is, however, not possible due to data limitations.
Time since first primary cancer
An increased health awareness or close follow-up by the
health care personnel may result in earlier diagnoses of
new cancers in CMM and SCC survivors compared to
that of the general cancer-free population [15,55].
Nevertheless, it is unlikely that this can fully explain the
observed elevated cancer risk. Higher risk was observed
in men than in women, and due to gender difference in
health vigilance, we would expect the opposite as
women more often interact with health care personnel
[64]. The nonlinear increase for SCC survivors may help
explain why the interaction terms between a skin cancer
diagnosis and calendar year were statistically significant
whereas the stratified analyses with a cut-point set arbi-
trarily in 1990 yielded overlapping confidence intervals
for CMM, but not for SCC.
Vitamin D
UVR promotes vitamin D synthesis and vitamin D is
demonstrated to regulate several genes involved in can-
cer processes and is hypothesized to inhibit cancer de-
velopment [38]. Inverse relationships between a history
of skin cancer, as a proxy of high vitamin D levels, and
risk of subsequent cancers support this hypothesis
[31,32,34-37], but the vitamin D hypothesis is not sup-
ported by the large number of studies that report in-
creased risks of second primary cancers after skin cancer
[9-30,33], and neither by the present results. We found
the highest risk of subsequent cancer in the South re-
gion, which has the highest UVR dose in Norway. Re-
cently, a study including four cohorts from different
regions of Norway observed a slightly higher mean level
of serum vitamin D in the cohort comprising residents
from the southern part of the country [65]. Therefore,
low levels of vitamin D might not explain our findings,
although we cannot exclude the possibility that individ-
uals with a history of skin cancer have insufficient vita-
min D-levels due to changed sun-exposure habits after
diagnosis. Results from a Danish study, however, coun-
ters this hypothesis as it demonstrates that previous
CMM patients not are more cautious sun bathers [66].
We can also not exclude that other effects of UVR ex-
posure, such as immunodeficiency, may play a role.
Limitations and strengths
The study has several obvious strengths including the
long time-span, covering more than 50 years of follow-
up, and the large study population, covering the entire
Norwegian population. Several cancers were diagnosed
in excess, but the highest risk was found for a subse-
quent skin cancer, particularly of similar type. General
practitioners and dermatologists interacting with skin
cancer survivors should be aware of this in their surveil-
lance and follow-up.
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Individual-level information on some potential con-
founding variables was available and was found to influ-
ence the risk estimates. Less adjusted models are thus
likely to over- or underestimate the real risk increase in
skin cancer survivors, depending on the direction of the
influence of excluded variables. A limitation of the study
is the lack of information on parental cancer in older
skin cancer survivors. Further, the use of a 20% sample
resulted in larger standard errors and thus wider confi-
dence intervals than would have been obtained if we had
included the whole population. This is particularly rele-
vant for the site-specific analyses of less common cancer
forms, but nevertheless unlikely to have impacted our
estimated significantly. Another limitation is the lack of
behavioral risk factors such as smoking habits, sun ex-
posure habits, body mass index (BMI), physical activity
etc., which would have given more direct information on
behavioral changes that may minimize the risk for a sec-
ond cancer. Lastly, as we chose to primarily focus on so-
cioeconomic factors at time of diagnosis, we are unable
to account for changes in these over the life course.
Such analyses would shed light on the relevance of de-
velopments in socioeconomic characteristics that have
taken place in Norway as well as in other industrialized
countries over the last 50 years. Nonetheless, there is lit-
tle reason to believe that the development has been
much different for skin cancer survivors compared to
the general population given that we adjusted for age,
calendar period and follow-up time.
Conclusions
Heightened public awareness may be important to pre-
vent subsequent cancers in skin cancer survivors as the
skin cancer incidence rates continue to rise. Of particu-
lar relevance to general practitioners and dermatologists
dealing with skin cancer survivors, is the need for en-
hanced surveillance for a new skin cancer. Further, our
results provide information on shared risk factors for
first and later cancers that may help in identifying indi-
viduals at high risk for subsequent cancers, and for
whom particular attention ought to be directed.
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